Why is Bafna Pharma. falling/rising?

As of 11-Jul, Bafna Pharmaceuticals Ltd is experiencing a decline in its stock price, currently at Rs 83.36, which represents a decrease of Rs 1.74 or 2.04%. The stock has been underperforming recently, having fallen consecutively for two days with a total decline of 2.96%. Today's performance shows that it has underperformed its sector by 2.62%. Additionally, the stock has touched an intraday low of Rs 82.63. Over the past week, the stock has decreased by 6.84%, while its one-month performance shows a positive return of 11.15%. However, it has generated a negative return of 6.65% over the past year, despite a healthy long-term growth in net sales and operating profit. The company maintains a strong ability to service debt, indicated by a low Debt to EBITDA ratio of 1.30 times, but its profits have fallen by 14.2% over the past year, which may be contributing to the current price decline.
In the broader market context, Bafna Pharmaceuticals' recent performance contrasts with the Sensex, which has only declined by 1.12% over the past week. This indicates that the stock is not only underperforming its sector but also lagging behind the overall market. The falling investor participation, with a significant drop in delivery volume by 76.8% against the 5-day average, suggests a lack of confidence among investors. While the stock is trading at a discount compared to its peers' average historical valuations, the recent negative returns and declining profits may be overshadowing its long-term growth potential, leading to the current downward trend in its stock price.